Colossal Biosciences sues ex-executive over alleged trade secret theft

Traders Union
All News
Business & Wealth
Companies
Colossal sues ex-executive

Highlights

Colossal Biosciences filed a U.S. federal lawsuit alleging ex-executive James Kehler stole trade secrets before joining Neion Bio and Felix Pets in April 2026.
The complaint links Kehler's access to multiplex genome editing and proprietary protocols at Colossal to recent advancements at Felix Pets in allergen-free kittens.
Colossal Biosciences was valued at $10.2 billion in January 2025 after a TWG Global-led round, highlighting intense investor focus on biotech intellectual property.

Lawsuit details and alleged data transfers

As reported by Financial Times, the Dallas-based start-up filed a lawsuit in U.S. federal court in Texas on Friday alleging that former executive James Kehler took trade secrets to support projects at competing ventures. Colossal said Kehler worked on efforts to revive the moa and dodo, as well as research into allergen-free cats, giving him access to multiplex genome editing, stem cell biology and proprietary animal protocols.

The complaint alleges that Kehler used his Colossal laptop to transfer confidential and trade secret material to a personal cloud account and personal devices before departing the company. Kehler did not immediately respond to a request for comment.

After resigning, Kehler joined Neion Bio in April 2026, a start-up focused on manufacturing medicines in chicken eggs. Colossal alleges the knowhow behind its de-extinction work overlaps with Neion's avian manufacturing processes and says Kehler brought its confidential information into those projects.

Colossal also alleges that Kehler took company secrets to Felix Pets, a business seeking to develop gene-edited cats for allergy sufferers. According to the complaint, Felix Pets' recent progress on allergen-free kittens coincides with Kehler's departure from Colossal and his arrival at the company.

High valuation puts biotech IP in focus

Founded in 2021 by entrepreneur Ben Lamm and geneticist George Church, Colossal describes itself as the world's first de-extinction company and says its mission is to limit biodiversity loss and restore damaged ecosystems. The company has attracted backing from investors including Mark Walter, In-Q-Tel and Paris Hilton, and it was valued at $10.2 billion in a January 2025 funding round led by TWG Global.

The start-up has drawn attention for plans to revive extinct species including the woolly mammoth, using Asian elephants as a basis organism, and it has promoted "woolly mice" as an early milestone. In April 2025, Colossal said it had completed what it called the first de-extinction by editing the grey wolf genome to restore the dire wolf and delivering pups from surrogate dogs.

This summer, Colossal announced a partnership with the U.S. government to collect and preserve genetic material from endangered species. Lamm also has a separate venture with Anduril co-founder Palmer Luckey to produce genetically enhanced working dogs for the military, a company that raised $200 million in a recent funding round including Sequoia Capital and In-Q-Tel.

Our earlier article on Chariot Claims’ $10 million Series A explained how the legal-tech startup is using AI and human review to help law firms process mass arbitration and other high-volume consumer claims tied to privacy issues, hidden fees, and hard-to-cancel subscriptions. We also noted that strong funding in legal tech is supporting tools that automate research using public court records and scale claim screening dramatically—context that underscores why lawsuits and legal processes are increasingly shaped by technology and data handling.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.